|
Welcome to the Chronic Lymphocytic Leukaemia Support Association (CLLSA), the UK's only charity specifically for Chronic Lymphocytic Leukaemia (CLL). The aim of this site is to be the leading one-stop resource for patients in the UK with CLL and their carers. We aim to provide accurate and up-to-date information on CLL in a patient friendly format. We hope that you find our services of value. Please register for your free membership of the association and we can then keep you informed of the latest information on CLL. Rituximab; Mabthera.
The NICE appraisal for ‘Rituximab for first line chronic lymphocytic leukaemia’ took place during early March. Rituximab is a mono clonal antibody that has been shown to lead to longer, deeper remissions in some CLL patients, when used as a combination therapy with other drugs already used routinely by the NHS. If the appraisal result is favourable, then Rituximab will be available to NHS doctors for CLL patients- but not for some months.Rituximab has been used for CLL in other parts of the world for some years; we await the result of the appraisal with intense interest. When we have a decision, we will ask for your comments.CLLSA sent 2 patient experts to the appraisal, and they both contributed a great deal of hard work. Medical experts included a representative from the UK CLL Forum.
|
|
Questions or problems regarding
this web site should be directed to the
CLL Support Association. |